key: cord-1034343-cmj210ne authors: Reddy, D. Himanshu; Atam, Virendra; Rai, Priyanka; Khan, Farman; Pandey, Saurabh; Malhotra, Hardeep Singh; Gupta, Kamlesh Kumar; Sonkar, Satyendra Kumar; Verma, Rajeev title: COVID-19 cases and their outcome among patients with uncommon co-existing illnesses: A lesson from Northern India date: 2022-04-12 journal: Clin Epidemiol Glob Health DOI: 10.1016/j.cegh.2022.101044 sha: 26b74ff1e5ba78ef2fb9c768e323623f7befc9b8 doc_id: 1034343 cord_uid: cmj210ne INTRODUCTION: Newer coexisting conditions should be identified in order to modify newer risk factors. Aim was to identify patients with non-classical or less common coexisting conditions in patients infected of COVID 19. METHOD: Single centred study from June 2020 to May 2021 at a tertiary centre in North India. A preformed questionnaire was used to record clinical and laboratory parameters and to identify cases which are in addition to CDC list and Indian data. RESULTS: 0.67% (46) cases out of 6832 patients were identified to have non-classical coexisting illness. It was divided into 2 groups-infections A (60.1%) and non-infections B (39.9%). Group A included-tuberculosis- pulmonary (14.3%) & extra pulmonary (32.9%), bacterial (25.0%) viral infections [dengue, hepatitis B & C] (14.3%), HIV disease (10.7%) and malaria (3.6%). Group B included- organ transplant (27.8%), autoimmune [myasthenia gravis, polymyositis, psoriasis] (22.6%), haematologic [Haemophilia, ITP, Aplastic anaemia, APML, CML] (27.8%), uncommon malignancies [disseminated sacral chordoma and GTN] (11.1%) and snakebite (11.1%). Serum Procalcitonin was not helpful for diagnosis of bacterial infection in COVID-19 disease. Group A had significantly longer duration of illness, hepatitis and elevated CRP. The mortality in group A & B were 32.1% and 43.8% respectively. Death in non-severe COVID cases was in tetanus and snakebite. 30.7% death among tuberculosis patients. More than 70% of deaths were attributable to COVID 19 in both the groups. CONCLUSION: In Indian settings, comorbidities like tuberculosis and bacterial infections can precipitate severe COVID 19 unlike other parts of the world where tuberculosis is relatively uncommon. Authors in the conduction of this study Introduction COVID-19 affected worldwide after its origin from Wuhan, China. It adversely affected people belonging to high risk group as defined by CDC (1) and this was uniformly observed across globe. CDC has laid down risk factors according to available evidences and strongest risk factors includes-cancer, CKD, COPD, cardiac illness, cerebrovascular accidents, smoker, obesity, pregnancy, solid organ or haematopoietic cells transplant and diabetes mellitus. The remaining factors had moderate to low level of evidences for severe diseases (1). As the disease continues to unfold itself new risk groups are expected. One such risk factor established later is tuberculosis as shown by Sarkar et al (2) . We started managing this pandemic since February 2020 and our initial report by D H Reddy et al shows presence of classical risk group and expected outcome (3) . Over the time during this pandemic we encountered COVID 19 disease with underlying illnesses sparsely described in literature and variable outcomes of this disease. Thereby, we are reporting uncommon co-existing illnesses with COVID19 disease and their outcome in Indian context of this pandemic. The study was conducted at COVID 19 treatment facility of a tertiary care centre in Northern India from June 2020 to May 2021. The patients admitted to the facility either by selfreporting for testing, contact tracing, positive test from community screening or elsewhere screening. We enrolled consecutive patients admitted with diagnosis of SARS-CoV-2 and evaluated them by pre-formed proforma to record epidemiology, history, examination and investigation. Hyperinflammation or cytokine response was defined as presence of two or more of the followingserum ferritin > 1000 ng/mL; C-reactive protein > 150 mg/L; D-dimer > 800 μg/L; Interleukin 6 > 20 pg/mL (5). All patients with any suspected or confirmed concurrent illness or recently diagnosed were included in the study. We used CDC criteria to identify comorbidities or coexisting illness (1). After review of these criteria in Indian context we concluded that the frequency of few diseases or conditions is low and therefore we considered keeping this group among uncommon co-existing condition. This included-Solid organ or blood stem cell transplantation cases, patients on immunosuppressive medications and uncommon cancers. The mandatory investigations included-complete blood count (CBC), liver function, kidney function test (KFT), serum electrolytes, serum C reactive protein, serum lactate dehydrogenase (LDH), ferritin, rapid testing for HbsAg, Anti-HCV IgG and HIV, EKG and chest x ray. Additional investigations were performed as per case The features positively correlating with infection by COVID-19 include fever with myalgia, fatigue along with dyspnoea, dry cough, absolute anosmia, aguesia. In this background the investigations included-neutrophilic leucocytosis, thrombocytosis, elevated levels of serum LDH, CRP, Pro-BNP, fibrinogen, procalcitonin and, D dimer with normal prothrombin time (6, 7). Serum Procalcitonin was done by ELISA method and all patients sample was sent on day of admission along with other routine investigations. All suspected or confirmed cases of chronic illness like tuberculosis; rheumatic diseases and malignancy in their active state were included and rest were excluded. Cases of Tuberculosis (pulmonary & extra-pulmonary) with duration of less than 2 months were included as active disease and longer duration were excluded from active co-existing illness. The coexisting illness were categorised as infectious and non-infectious. Death attributable to COVID-19 was adapted from WHO guidelines (8). All patients were followed up till discharge from hospital or expiry. Statistical analysis was performed using SPSS software (version 25.0, IBM, Armonk, NY). Normally distributed data were presented as mean ± SD and data with a skewed distribution as median (IQR). The between groups differences were determined by using Student's t-test, analysis of variance (ANOVA), and nonparametric tests (Chi-square test) as well as Student's t-test being used for comparison with paired samples. In all statistical results, P < .05 was defined as statistical significance. * indicates statistical significance (*P < .05, **P < .01, ***P < .001, ****P < .0001). Ethical clearance was provided by institutional ethical committee. In our study we evaluated 6832 patients admitted in COVID-19 dedicated care and 46 (0.67 %) had uncommon or non-classical co-existing illnesses. These are clubbed in 2 groups as infections and non-infections with 63.6 % of infections as co-existing illness. The table 1 (Distribution of non-classical co-existing and concurrent illness in patients of COVID- 19) shows distribution of coexisting illnesses. The infections group has significantly higher cases of tuberculosis 13 (56.4%) both pulmonary 4 (14.3%) and extra-pulmonary 9 (32.1%) followed by bacterial infections 7 (25%). There were 2 cases of sputum positive with rifampicin sensitive pulmonary tuberculosis (50%) and rest were diagnosed clinicoradiologically. 2 (22.2%) patients of extra-pulmonary tuberculosis were CBNAAT positive and rest were based on clinical, radiological and cytology study. The EPTB cases included-3 cases of pleural effusion, 2 cases of tuberculous meningitis, 1 each cases of pyothorax, lymph node TB, tuberculoma, and disseminated TB. All suspected tuberculosis patients clinical features of fever with sputum for more than 1 month and in EPTB cases the duration of illness raned between 1 to 3 months. We included cases of more than 1 month of duration of illness so as to prevent over diagnosis of tuberculosis in background of COVID 19. 5 patients were already of antituberculous drugs and 2 were initiated. All bacterial infections diagnosed on basis of positive culture except 2 (pyelonephritis and intra-abdominal sepsis) due to prior antibiotics use. Malaria and 2 dengue cases were diagnosed according to WHO criteria with malaria as uncomplicated illness and each case of dengue as sever and non-severe. The comparative data of both the groups are depicted in Dengue fever with warning signs at end of critical phase developed severe COVID pneumonia and expired on 5 th day. 3 patients with features suggestive of HLH were subjected to bone marrow study but were inconclusive and diagnosed as cytokine storm. Severe form of COVID-19 is usually seen in presence of certain risk factors and they are classical risk factors. We considered the CDC criteria and found few coexisting illnesses apart from classical risk factors. In our study classical risk factors were seen in 38.6% of all patients without any significant differences among both groups. In fact, these factors were present in 15.9% of all cases with sever disease. (19) . Similarly, 2 cases of myasthenia gravis on immunosuppression and one of them succumbed to sever COVID19 disease while the other recovered a moderate illness. We had a recently diagnosed ITP patient on prednisolone more than 10 mg per day developed progressive thrombocytopenia and moderate COVID disease that responded to pulse methyl prednisolone. American society of haematology (ASH) mentions ITP as not a risk factor for severe COVID 19 disease (20) . The other unreported case in Indian setting is COVID19 among Haemophilia patients. Since haemophilia is coagulation disorder treatment of COVID 19 coagulation defects poses a challenging task and especially in severe cases as shown by De la Corte-Rodriguez H et al but fortunately it not a risk factor for severe COVID 19 disease (21) . Our patient recovered a mild illness with complete recovery and no coagulation defect. We report a newly diagnosed untreated case of CML without other comorbidities developed severe COVID disease and recovered. W Li et al found that CML patients are at higher risk of developing COVID disease with advance illness and comorbidities carries poor prognosis (22) . Similarly, we diagnosed a case of acute promyelocytic leukemia who presented to us with high grade ever with pancytopenia and on evaluation came COVID positive and during stay developed DIC and ARDS. A similar case is reported by Farmer I et al from London but none from India (23). We diagnosed 2 cases of GTN with one recovered moderate COVID disease the other with disseminated disease died from ARDS. Bachani S et al had 1 patient died from GTN post operatively among COVID infected pregnant female (24) . We found almost no significant difference among laboratory parameters of the patients among both groups showing uniform COVID disease activity among the groups. Procalcitonin as marker of gram negative bacterial infection and it stay elevated in COVID 19 and its levels are directly proportional to the severity of COVID 19 disease (25) . In our study 91% patients with severe disease had elevated levels (0.6-53.8 ng/l) without any significant difference with patients with bacterial infection. About 44% patient had thrombocytopenia and more than 60% of severe thrombocytopenia cases were seen in patients with haematological disorders, and each case of dengue fever, malaria and severe sepsis indicating severe thrombocytopenia as differentiating feature for COVID 19 infection. The unique feature of elevated d-dimer with fibrinogen (6) was seen around 23% cases without any difference amongst the group predominantly in severe disease group showing COVID 19 activity. 37.5% mortality was seen with attributable death of 72.2% evenly distributed in both groups showing COVID disease as predominant cause of death. Severe COVID 19 disease is associated with commonly occurring classical risk factors across globe. In Indian context there is possibility of newer coexisting illness that might precipitate severe COVID 19 disease in form of tuberculosis and bacterial infections apart from prolonged immunosuppression and uncommon malignancy as gestational trophoblastic neoplasm, myasthenia gravis and solid organ transplants. These are sparse findings in Indian settings and require close monitoring for severe disease even in absence of classical risk factors. Death attributed to COVID 19 is usually high hence these might be additional risk factors. Co-existing illness: infectious (n= 28) Co-existing illness: non-infectious (n= 18) Extra-pulmonary tuberculosis (9) [32.1%] -Central nervous system tuberculosis (7) -Tubercular meningitis ± tuberculoma ( Impact of COVID-19 in patients with concurrent coinfections: A systematic review and meta-analyses An Initial Profile and Virological Response of SARS-CoV-2 Infected Patients Admitted to Infectious Diseases Hospital of Northern India The unique characteristics of COVID-19 coagulopathy. Crit Care Extrapulmonary manifestations of COVID-19: Radiologic and clinical overview Active tuberculosis, sequelae and COVID-19 coinfection: first cohort of 49 cases Tuberculosis, COVID-19 and migrants: Preliminary analysis of deaths occurring in 69 patients from two cohorts. Pulmonology Mortality due to TB-COVID-19 coinfection in India A profile of a retrospective cohort of 22 patients with COVID-19 and active/treated tuberculosis COVID-19 Researchers Group. Incidence of coinfections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study COVID-19 in Post-Operative Patients: Imaging Findings Rheumatic disease and COVID-19: epidemiology and outcomes Clinical profile of SARSA CoV-2 infection in kidney transplant patients-A single centre observational study COVID-19 in Liver Transplant Recipients -A Series with Successful Recovery Outcomes of Coronavirus Disease 2019 in Living Donor Liver Transplant Recipients COVID-19 Induced Hepatitis B Virus Reactivation: A Novel Case From the United Arab Emirates. Cureus What COVID-19 can mean for people with hemophilia beyond the infection risk COVID-19 in persons with chronic myeloid leukaemia Acute promyelocytic leukaemia lying under the mask of COVID-19-a diagnostic and therapeutic conundrum Clinical Profile, Viral Load, Maternal-Fetal Outcomes of Pregnancy With COVID-19: 4-Week Retrospective, Tertiary Care Single-Centre Descriptive Study Prognostic Value of Serum Procalcitonin in COVID-19 Patients: A Systematic Review # Diseases marked in red shows cases of expiry J o u r n a l P r e -p r o o f